ChanockS.Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am.1993; 7: 771–793.
2.
PizzoP.A.Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med.1993; 328: 1323–1332.
3.
ViscoliC., BruzziP., CastagnolaE.Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer.1994; 30: 430–437.
4.
BodeyG.P., BuckleyM., SatheY.S.Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med.1966; 64: 328–340.
5.
StraussR.G.Granulocyte transfusion therapy. Hematol Oncol Clin North Am.1994; 8: 1159–1166.
StraussR.G.Therapeutic neutrophil transfusions: are controlled studies no longer appropriate?Am J Med.1978; 65: 1001–1006.
8.
ChanockS., FreifeldA.The use of cytokines in fever and neutropenia. Int J Pediatr Hematol Oncol.1995; 2: 173.
9.
WalshT.J.Management of immunocompromised patients with evidence of an invasive mycosis. Hematol Oncol Clin North Am.1993; 7: 1003–1026.
10.
DoddR.Y.The risk of transfusion-transmitted infection. N Engl J Med.1992; 327: 419–421.
11.
JeterE.K., SpiveyM.A.Noninfectious complications of blood transfusion. Hematol Oncol Clin North Am.1995; 9: 187–204.
12.
RubinM., PizzoP.Controversial issues in antibacterial management of cancer patients. In: WiernikP., ed. Mediguide to Oncology.1986: 1
13.
BhatiaS., McCulloughJ., PerryE.H.Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion.1994; 34: 226–232.
14.
WalshT.J., PizzoA.Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis.1988; 7: 460–475.
15.
AlaviJ.B., RootR.K., DjerassiI.A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med.1977; 296: 706–711.
16.
FortunyI.E., BloomfieldC.D., HadlockD.C.Granulocyte transfusion: a controlled study in patients with acute non-lymphocytic leukemia. Transfusion.1975; 15: 548–558.
17.
GrawR.G.Jr, HerzigG., PerryS.Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med.1972; 287: 367–371.
18.
HerzigR.H., HerzigG.P., GrawR.G.Jr. Successful granulocyte transfusion therapy for gram-negative septicemia: a prospectively randomized controlled study. N Engl J Med.1977; 296: 701–705.
19.
HigbyD.J., YatesJ.W., HendersonE.S.Filtration leukapheresis for granulocyte transfusion therapy: clinical and laboratory studies. N Engl J Med.1975; 292: 761–766.
20.
VoglerW., WinstonE.A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med.1977; 63: 548–555.
21.
WinstonD.J., HoW.G., GaleR.P.Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med.1982; 97: 509–515.
22.
McCulloughJ.M., ClayM.E.Granulocyte alloantigen systems and their clinical significance. In: NanstS.T., ed. Alloimmunity: 1993 and Beyond.Bethesda, Md: American Academy of Blood Banks; 1993: 49.
23.
HillH.R.Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res.1987; 22: 375–382.
24.
BrzicaS.M.Jr, PinedaA.A., TaswellH.F.Chronic granulomatous disease and the Mcleod phenotype: successful treatment of infection with granulocyte transfusions resulting in subsequent hemolytic transfusion reaction. Mayo Clin Proc.1977; 52: 153–156.
25.
BuescherE.S., GallinJ.I.Leukocyte transfusions in chronic granulomatous disease: persistence of transfused leukocytes in sputum. N Engl J Med.1982; 307: 800–803.
26.
ChusidM.J., TomasuloP.A.Survival of transfused normal granulocytes in a patient with chronic granulomatous disease. Pediatrics.1978; 61: 556–559.
27.
PedersenF.K., JohansenK.S., RosenkvistJ.Refractory Pneumocystis carinii infection in chronic granulomatous disease: successful treatment with granulocytes. Pediatrics.1979; 64: 935–938.
28.
YomtovianR., AbramsonJ., QuieP.Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion.1981; 21: 739–743.
29.
EzekowitzR.A., OrkinS.H., NewburgerP.E.Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest.1987; 80: 1009–1016.
30.
The International Chronic Granulomatous Disease Cooperative Study Group.A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med.1991; 324: 509–516.
31.
CairoM.S.The use of granulocyte transfusion in neonatal sepsis. Transfus Med Rev.1990; 4: 14–22.
32.
StraussR.G.Current status of granulocyte transfusions to treat neonatal sepsis. J Clin Apheresis.1989; 5: 25–29.
33.
CairoM.S., RuckerR., BennettsG.A.Improved survival of newborns receiving leukocyte transfusions for sepsis. Pediatrics.1984; 74: 887–892.
34.
ChristensenR.D., RothsteinG., AnstallH.B.Granulocyte transfusions in neonates with bacterial infection, neutropenia and depletion of mature marrow neutrophils. Pediatrics.1982; 70: 1–6.
35.
American Society of Clinical Oncology.Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol.1994; 12: 2471–2508.
36.
BoogaertsM., CavalliF., Cortes-FunesH.Granulocyte growth factors: achieving a consensus. Ann Oncol.1995; 6: 237–244.
37.
BenderJ.G., UnverzagtK., WalkerD.E.Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation. Clin Immunol Immunopath.1994; 70: 10–18.
38.
BeyerJ., SchwellaN., ZingsemJ.Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol.1995; 13: 1328–1335.
BensingerW.I., PriceT.H., DaleD.C.The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood.1993; 81: 1883–1888.
41.
CasparC.B., SegerR.A., BurgerJ.Effective stimulation of donors for granulocyte transfusions with recombinant meth-ionyl granulocyte colony-stimulating factor. Blood.1993; 81: 2866–2871.
42.
ThelenM., DewaldB., BaggioliniM.Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev.1993; 73: 797–821.
43.
RoilidesE., WalshT.J., PizzoP.A.Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis.1991; 163: 579–583.
44.
RoilidesE., PizzoP.A.Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis.1992; 15: 508–524.
45.
BrachM.A., deVosS., GrussH.J.Prolongation of survival of human polymor-phonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood.1992; 80: 2920–2924.
46.
ColottaF., ReF., PolentaruttiN.Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood.1992; 80: 2012–2020.
47.
CoxG., GauldieJ., JordanaM.Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils in vitro. Am J Respir Cell Mol Biol.1992; 7: 507–513.
48.
AdachiS., KubotaM., LinY.W.In vivo administration of granulocyte colony-stimulating factor promotes neutrophil survival in vitro. Eur J Hematol.1994; 53: 129–134.
49.
CohenD., BhatiaS., AnaissieE.Protection of human neutrophils from deleterious effects of isolation, irradiation, and storage by interferon-gamma and G-CSF. Infect Dis Soc Am.1993; 38A: 222.
50.
KlebanoffS.J., OlszowskiS., Van VoorhisW.C.Effects of gamma-interferon on human neutrophils: protection from deterioration on storage. Blood.1992; 80: 225–234.
51.
AABB: Standards for Blood Banks and Transfusion Services.16th ed.Bethesda, Md: American Academy of Blood Banks; 1994.
52.
LeeJ., LeitmanS.A controlled study of the efficacy of hetastarch and pentastarch in granulocyte collection by centrifugal leukapheresis. Transfusion.1994; 34: 59.
53.
BowdenR.A.Transfusion-transmitted cytomegalovirus infection. Hematol Oncol Clin North Am.1995; 9: 155–166.
WrightD.G., RobichaudK.J., PizzoP.A.Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med.1981; 304: 1185–1189.
57.
AndersonK.C., WeinsteinH.J.Transfusion-associated graft-versus-host disease. N Engl J Med.1990; 323: 315–321.
58.
EastlundD.T., CharbonneauT.T.Superoxide generation and cytotactic response of irradiated neutrophils. Transfusion.1988; 28: 368–370.
59.
WheelerJ.G., AbramsonJ.S., EkstrandK.Function of irradiated polymorphonuclear leukocytes obtained by buffy coat centrifugation. Transfusion.1984; 24: 238–239.
MillerL.L.Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology.1994; 7: 67–78, 81–84,87–88.
62.
SaarinenU.M., HoviL., VilinikkaL.Reemphasis on leukocyte transfusions: induction of myeloid marrow recovery in critically ill neutropenic children with cancer. Vox Sang.1995; 68: 90–99.
63.
AbrahamsenT.G., CarterC.S., ReadE.J.Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cell at 37 degrees C. J Clin Apheresis.1991; 6: 48–53.
64.
GaoI.K., NogaS.J., WagnerJ.E.Implementation of a semiclosed large scale counterflow centrifugal elutriation system. J Clin Apheresis.1987; 3: 154–160.
65.
YasakaT., MantichN.M., BoxerL.A.Functions of human monocyte and lymphocyte subsets obtained by countercurrent centrifugal elutriation: differing functional capacities of human monocyte subsets. J Immunol.1981; 127: 1515–1518.
66.
MandellG.L.Delivery of antibiotics by phagocytes. Clin Infect Dis.1994; 19: 922–925.
